Cargando…
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies
BACKGROUND: The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to either receive the standard chemotherapy treatment or a biomarker-directed treatment arm, in which biomarker status i...
Autores principales: | Wason, J, Marshall, A, Dunn, J, Stein, R C, Stallard, N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992506/ https://www.ncbi.nlm.nih.gov/pubmed/24667651 http://dx.doi.org/10.1038/bjc.2014.156 |
Ejemplares similares
-
An adaptive biomarker strategy clinical trial design
por: Wason, James, et al.
Publicado: (2013) -
A Bayesian adaptive design for biomarker trials with linked treatments
por: Wason, James M S, et al.
Publicado: (2015) -
A multi-stage drop-the-losers design for multi-arm clinical trials
por: Wason, James, et al.
Publicado: (2016) -
An adaptive trial design for updating the threshold of a continuous biomarker
por: Spencer, Amy, et al.
Publicado: (2015) -
Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial
por: Pinder, S E, et al.
Publicado: (2017)